ADENOSINE injection

Nazione: Stati Uniti

Lingua: inglese

Fonte: NLM (National Library of Medicine)

Principio attivo:

Adenosine (UNII: K72T3FS567) (Adenosine - UNII:K72T3FS567)

Commercializzato da:

Sagent Pharmaceuticals

Via di somministrazione:

INTRAVENOUS

Tipo di ricetta:

PRESCRIPTION DRUG

Indicazioni terapeutiche:

Intravenous adenosine injection is indicated for the following. Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver), should be attempted prior to adenosine injection administration. It is important to be sure the adenosine injection solution actually reaches the systemic circulation (see DOSAGE AND ADMINISTRATION ). Adenosine Injection does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. In the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine injection administration. Intravenous adenosine injection is contraindicated in: - Second- or third-degree A-V block (except in patients with a functioning artificial pacemaker). - Sinus node disease, such as sick sinus syndrome or sy

Dettagli prodotto:

Adenosine Injection, USP is supplied as a sterile non-pyrogenic solution in normal saline. Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] DO NOT REFRIGERATE as crystallization may occur. If crystallization has occurred, dissolve crystals by warming to room temperature. The solution must be clear at the time of use. Discard unused portion. Sterile, Nonpyrogenic, Preservative-free. The container closure is not made with natural rubber latex.

Stato dell'autorizzazione:

Abbreviated New Drug Application

Scheda tecnica

ADENOSINE- ADENOSINE INJECTION
SAGENT PHARMACEUTICALS
----------
ADENOSINE INJECTION, USP
FOR RAPID BOLUS INTRAVENOUS USE
SAGENT
Rx only
DESCRIPTION
Adenosine is an endogenous nucleoside occurring in all cells of the
body. It is chemically
6-amino-9-β-D-ribofuranosyl-9-H-purine and has the following
structural formula:
Adenosine is a white crystalline powder. It is soluble in water and
practically insoluble in
alcohol. Solubility increases by warming and lowering the pH.
Adenosine is not chemically
related to other antiarrhythmic drugs. Adenosine Injection is a
sterile, nonpyrogenic
®
solution for rapid bolus intravenous injection. Each mL contains 3 mg
adenosine and 9
mg sodium chloride in Water for Injection. The pH of the solution is
between 4.5 and 7.5.
CLINICAL PHARMACOLOGY
MECHANISM OF ACTION
Adenosine Injection slows conduction time through the A-V node, can
interrupt the
reentry pathways through the A-V node, and can restore normal sinus
rhythm in
patients with paroxysmal supraventricular tachycardia (PSVT),
including PSVT associated
with Wolff-Parkinson-White Syndrome.
Adenosine Injection is antagonized competitively by methylxanthines
such as caffeine
and theophylline, and potentiated by blockers of nucleoside transport
such as
dipyridamole. Adenosine Injection is not blocked by atropine.
HEMODYNAMICS
The intravenous bolus dose of 6 or 12 mg adenosine injection usually
has no systemic
hemodynamic effects. When larger doses are given by infusion,
adenosine decreases
blood pressure by decreasing peripheral resistance.
PHARMACOKINETICS
Intravenously administered adenosine is rapidly cleared from the
circulation via cellular
uptake, primarily by erythrocytes and vascular endothelial cells. This
process involves a
specific transmembrane nucleoside carrier system that is reversible,
nonconcentrative,
and bidirectionally symmetrical. Intracellular adenosine is rapidly
metabolized either via
phosphorylation to adenosine monophosphate by adenosine kinase, or via
deamination
to inosine by adenosine deaminase in